Items 71 ~ 80 of 5389, Page 8 of 539 
  06/20/2019 WHO - Public Health
WHO highlights scarcity of treatment for epilepsy in low-income countries
- Premature death is three times higher in people with epilepsy / Stigma is widespread / Treatment for epilepsy can be integrated into primary health services / 25% epilepsy cases can be prevented
  06/20/2019 American Medical Association (AMA) - Public Health
AMA: Senate HELP Bill on surprise billing fails to fix a broken system
  06/20/2019 American Academy of Ophthalmology - Public Health
Reports of Eye Injuries From Fireworks Have Doubled
- American Academy of Ophthalmology offers tips on how to stay safe around fireworks
  06/20/2019 MERCK - Business
Merck Hosts 2019 Investor Day Outlining Business Momentum, Strong Expected Growth and Focus on Innovative Research and Development
  06/19/2019 WHO - Public Health
WHO flags critical funding gap, calls for political parties to join fight against Ebola
- WHO Director-General briefs Members States on situation in DRC and appeals for funding for the Ebola response
  06/19/2019 MERCK - Business
AstraZeneca and Merck’s LYNPARZA® (olaparib) Approved in Japan as First-Line Maintenance Therapy in Patients with BRCA-Mutated Advanced Ovarian Cancer
- LYNPARZA is the Only PARP Inhibitor Approved in Japan
  06/18/2019 WHO - Public Health
In the face of slow progress, WHO offers a new tool and sets a target to accelerate action against antimicrobial resistance
  06/18/2019 WHO - Public Health
1 in 3 people globally do not have access to safe drinking water ? UNICEF, WHO
- New report on inequalities in access to water, sanitation and hygiene also reveals more than half of the world does not have access to safe sanitation services.
  06/18/2019 MERCK - Business
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy for Patients with Metastatic Small Cell Lung Cancer (SCLC) with Disease Progression on or After Platinum-Based Chemotherapy and at Least One Other Prior Line of Therapy
- Marks First Approval for KEYTRUDA in SCLC
  06/18/2019 MERCK - Business
LYNPARZA® (olaparib) Approved in the EU for Use as First-Line Maintenance Therapy in Patients With BRCA-Mutated Advanced Ovarian Cancer
- AstraZeneca and Merck’s LYNPARZA Reduced the Risk of Disease Progression or Death by 70% Compared to Placebo Following Response to Platinum-Based Chemotherapy in Phase 3 SOLO-1 Trial / LYNPARZA is the Only PARP Inhibitor Approved in the EU for This Indication

<<  <  [1]  [2]  [3]  [4]  [5]  [6]  [7]  [8[9]  [10]  >  >>